Inhibition of PAK1 disrupts immune evasion facilitated by pancreatic stellate cells (PSCs) in pancreatic ductal adenocarcinoma (PDA), thereby concomitantly decreasing inherent PD-L1 expression in PDA cells influenced by both endogenous factors and PSCs [107]. This evidence concerns the gene CD274 and Patent ductus arteriosus.